Loading...

Minerva Neurosciences

DB:4MN
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4MN
DB
$284M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The last earnings update was 44 days ago. More info.


Add to Portfolio Compare Print
4MN Share Price and Events
7 Day Returns
3.4%
DB:4MN
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
16.7%
DB:4MN
-5.6%
DE Biotechs
-4.5%
DE Market
4MN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Minerva Neurosciences (4MN) 3.4% -4.8% 4.1% 16.7% - -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 4MN outperformed the Biotechs industry which returned -5.6% over the past year.
  • 4MN outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
4MN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Minerva Neurosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Minerva Neurosciences to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Minerva Neurosciences.

DB:4MN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:4MN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 21%) (0%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.303 * 5.96%)
8%

Discounted Cash Flow Calculation for DB:4MN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Minerva Neurosciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:4MN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8%)
2019 -53.00 Analyst x1 -49.08
2020 -75.80 Analyst x1 -64.99
2021 -65.20 Analyst x1 -51.76
2022 -8.80 Analyst x1 -6.47
2023 43.80 Analyst x1 29.81
2024 51.83 Est @ 18.32% 32.67
2025 58.51 Est @ 12.89% 34.15
2026 63.83 Est @ 9.09% 34.49
2027 67.94 Est @ 6.43% 33.99
2028 71.04 Est @ 4.57% 32.92
Present value of next 10 years cash flows $25.73
DB:4MN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $71.04 × (1 + 0.23%) ÷ (8% – 0.23%)
$916.57
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $916.57 ÷ (1 + 8%)10
$424.69
DB:4MN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $25.73 + $424.69
$450.42
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $450.42 / 39.03
$11.54
DB:4MN Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:4MN represents 0.88611x of NasdaqGM:NERV
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88611x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 11.54 x 0.88611
€10.23
Value per share (EUR) From above. €10.23
Current discount Discount to share price of €6.44
= -1 x (€6.44 - €10.23) / €10.23
37%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Minerva Neurosciences is available for.
Intrinsic value
37%
Share price is €6.44 vs Future cash flow value of €10.23
Current Discount Checks
For Minerva Neurosciences to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Minerva Neurosciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Minerva Neurosciences's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Minerva Neurosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Minerva Neurosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4MN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.29
NasdaqGM:NERV Share Price ** NasdaqGM (2019-04-25) in USD $7.27
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Minerva Neurosciences.

DB:4MN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:NERV Share Price ÷ EPS (both in USD)

= 7.27 ÷ -1.29

-5.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Minerva Neurosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Minerva Neurosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Minerva Neurosciences's expected growth come at a high price?
Raw Data
DB:4MN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.62x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
30%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Minerva Neurosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Minerva Neurosciences's assets?
Raw Data
DB:4MN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.32
NasdaqGM:NERV Share Price * NasdaqGM (2019-04-25) in USD $7.27
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:4MN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:NERV Share Price ÷ Book Value per Share (both in USD)

= 7.27 ÷ 2.32

3.14x

* Primary Listing of Minerva Neurosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Minerva Neurosciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Minerva Neurosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Minerva Neurosciences has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Minerva Neurosciences expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
30%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Minerva Neurosciences expected to grow at an attractive rate?
  • Minerva Neurosciences's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Minerva Neurosciences's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Minerva Neurosciences's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:4MN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:4MN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 30%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4MN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4MN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 247 51 1
2022-12-31 152 -8 1
2021-12-31 54 -71 1
2020-12-31 0 -81 1
2019-12-31 0 -58 2
DB:4MN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -42 -50
2018-09-30 -41 -37
2018-06-30 -6 -36
2018-03-31 -2 -33
2017-12-31 3 -32
2017-09-30 3 -41
2017-06-30 -26 -38
2017-03-31 -26 -34
2016-12-31 -26 -31
2016-09-30 -23 -30
2016-06-30 -24 -28
2016-03-31 -25 -29

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Minerva Neurosciences's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Minerva Neurosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4MN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Minerva Neurosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4MN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.02 1.02 1.02 1.00
2022-12-31 -0.15 -0.15 -0.15 1.00
2021-12-31 -1.50 -1.50 -1.50 1.00
2020-12-31 -1.77 -1.77 -1.77 1.00
2019-12-31 -1.38 -1.35 -1.40 2.00
DB:4MN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.29
2018-09-30 -0.95
2018-06-30 -0.92
2018-03-31 -0.86
2017-12-31 -0.83
2017-09-30 -1.11
2017-06-30 -1.08
2017-03-31 -1.00
2016-12-31 -0.99
2016-09-30 -1.04
2016-06-30 -1.04
2016-03-31 -1.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Minerva Neurosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Minerva Neurosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Minerva Neurosciences has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Minerva Neurosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Minerva Neurosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Minerva Neurosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Minerva Neurosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Minerva Neurosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Minerva Neurosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Minerva Neurosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4MN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -50.17 16.84 34.89
2018-09-30 -36.81 15.21 32.42
2018-06-30 -36.05 13.61 33.01
2018-03-31 -33.30 12.34 31.09
2017-12-31 -31.52 10.91 30.26
2017-09-30 -41.09 10.66 30.21
2017-06-30 -38.25 10.59 27.11
2017-03-31 -33.69 10.24 22.68
2016-12-31 -31.05 9.75 20.44
2016-09-30 -30.08 8.95 20.20
2016-06-30 -27.60 8.44 18.18
2016-03-31 -28.99 8.04 19.95
2015-12-31 -27.08 7.58 18.53
2015-09-30 -26.08 10.12 15.24
2015-06-30 -47.30 10.59 36.21
2015-03-31 -60.06 11.84 46.28
2014-12-31 -56.90 11.96 42.91
2014-09-30 -51.59 9.35 40.10
2014-06-30 -24.92 7.29 15.50
2014-03-31 -5.93 4.32 1.19
2013-12-31 -3.26 2.45 0.71
2013-09-30 -1.43 0.77 0.66
2012-12-31 -1.58 1.03 0.55

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Minerva Neurosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Minerva Neurosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Minerva Neurosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Minerva Neurosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Minerva Neurosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Minerva Neurosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Minerva Neurosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Minerva Neurosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Minerva Neurosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Minerva Neurosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Minerva Neurosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Minerva Neurosciences Company Filings, last reported 3 months ago.

DB:4MN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 90.26 0.00 88.00
2018-09-30 101.39 0.00 97.61
2018-06-30 110.66 1.40 108.49
2018-03-31 121.29 2.70 121.00
2017-12-31 131.60 3.96 128.16
2017-09-30 130.18 5.19 132.93
2017-06-30 98.03 6.39 77.57
2017-03-31 106.29 7.56 85.36
2016-12-31 105.98 8.69 82.98
2016-09-30 113.14 9.80 91.85
2016-06-30 120.61 10.10 97.06
2016-03-31 66.65 10.02 44.64
2015-12-31 55.32 9.94 32.20
2015-09-30 63.07 9.86 37.49
2015-06-30 68.38 9.78 35.39
2015-03-31 74.44 9.71 52.20
2014-12-31 51.50 0.00 18.55
2014-09-30 56.72 0.00 23.64
2014-06-30 29.23 3.39 0.48
2014-03-31 34.09 0.83 2.14
2013-12-31 20.18 0.06 1.82
2013-09-30 0.73 0.00 1.10
2012-12-31 0.02 0.00 0.20
  • Minerva Neurosciences has no debt.
  • Minerva Neurosciences has no debt compared to 5 years ago when it was 0.3%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Minerva Neurosciences has sufficient cash runway for 2.1 years based on current free cash flow.
  • Minerva Neurosciences has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of -4.1% each year.
X
Financial health checks
We assess Minerva Neurosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Minerva Neurosciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Minerva Neurosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Minerva Neurosciences dividends. Estimated to be 0% next year.
If you bought €2,000 of Minerva Neurosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Minerva Neurosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Minerva Neurosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4MN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:4MN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Minerva Neurosciences has not reported any payouts.
  • Unable to verify if Minerva Neurosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Minerva Neurosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Minerva Neurosciences has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Minerva Neurosciences's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Minerva Neurosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Minerva Neurosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Minerva Neurosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Minerva Neurosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rémy Luthringer
COMPENSATION $2,280,316
AGE 57
TENURE AS CEO 4.4 years
CEO Bio

Dr. Rémy Luthringer, Ph.D., has been Executive Chairman of Minerva Neurosciences, Inc. since February 2018. Dr. Luthringer has been the Chief Executive Officer of Minerva Neurosciences, Inc. since November 2014 and served as its President from November 2014 to December 2017. Mr. Luthringer serves as Advisor at Index Ventures. He joined Index Ventures in 2010 and established the Geneva office. Dr. Luthringer serves as an Advisor at Medicxi Ventures. He serves as the Chief Medical Officer at the Index Life VI biotech fund raised by Index Ventures in 2012. He served as the Chief Scientific Officer at Minerva Neurosciences, Inc. He served as an Executive Vice President and Head of Research & Development at Minerva Neurosciences Inc. since March 2014. He has provided consulting services to Minerva Neurosciences since January 2011. He served as the Chief Medical Officer and Partner at Index Ventures since December 2010. He served as the Chief Executive Officer at Groupe FORENAP and FORENAP Pharma EURL. He served as the Chief Executive Officer and President at the FORENAP Institute for Research in Neurosciences and Neuropsychiatry from 2005 to September of 2010. He served as the Chief Executive Officer at one of the research institutes in neurosciences. He had advisory roles in several companies including the following: Funxional Therapeutics, Linguaflex and V-Watch. He has been a Director of Minerva Neurosciences, Inc. since November 2014. He serves as a Member of Scientific Advisory Board at Index Life VI. He has been a Member of the Scientific Advisory Board of Somnus Therapeutics, Inc. since November 2008. He was involved in several European grants and research programs focusing on development and validation of biomarkers or surrogate endpoints. He served on advisory boards of biotech as well as pharmaceutical companies and was involved in the development of more than 150 CNS active molecules and has carried out more than 700 clinical trials. He spent some years in clinical psychiatric practice. He focuses on investments in life sciences, healthcare infrastructure in Switzerland, France and United Kingdom. Dr. Luthringer received a Ph.D. in Neurosciences and in Clinical Pharmacology from University Louis Pasteur, France. He received a Masters Degree in Functional Explorations and Computer Engineering from University Paris VI, France and a obtained a Nursing Degree in Psychiatry from Rouffach Hosptial, France.

CEO Compensation
  • Rémy's compensation has been consistent with company performance over the past year.
  • Rémy's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Minerva Neurosciences management team in years:

4
Average Tenure
57
Average Age
  • The tenure for the Minerva Neurosciences management team is about average.
Management Team

Rémy Luthringer

TITLE
Executive Chairman & CEO
COMPENSATION
$2M
AGE
57
TENURE
4.4 yrs

Geoff Race

TITLE
Executive VP
COMPENSATION
$2M
AGE
57
TENURE
4.9 yrs

Michael Davidson

TITLE
Chief Medical Officer
COMPENSATION
$3M
AGE
68
TENURE
2.3 yrs

Rick Russell

TITLE
President
AGE
54
TENURE
1.3 yrs

Joe Reilly

TITLE
Senior VP & COO
COMPENSATION
$1M
AGE
43
TENURE
4.8 yrs

Fred Ahlholm

TITLE
Senior VP & Chief Accounting Officer
COMPENSATION
$845K
AGE
52
TENURE
4.8 yrs

William Boni

TITLE
Vice President of Investor Relations & Corporate Communications
AGE
66
TENURE
3.7 yrs

Devin Smith

TITLE
Senior VP
AGE
50
TENURE
0.8 yrs

Jay Saoud

TITLE
Senior VP and Head of Research & Development
AGE
59
Board of Directors Tenure

Average tenure and age of the Minerva Neurosciences board of directors in years:

1.3
Average Tenure
60
Average Age
  • The average tenure for the Minerva Neurosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jan van Heek

TITLE
Independent Director
COMPENSATION
$128K
AGE
69
TENURE
4.8 yrs

Rémy Luthringer

TITLE
Executive Chairman & CEO
COMPENSATION
$2M
AGE
57
TENURE
1.2 yrs

Fouzia Laghrissi-Thode

TITLE
Director
COMPENSATION
$122K
AGE
55
TENURE
3.9 yrs

David Kupfer

TITLE
Director
COMPENSATION
$117K
AGE
77
TENURE
3.4 yrs

Bill Doyle

TITLE
Lead Independent Director
COMPENSATION
$163K
AGE
56
TENURE
1.2 yrs

Hans Hasler

TITLE
Director
COMPENSATION
$163K
AGE
62
TENURE
1.3 yrs

Jeri Hilleman

TITLE
Independent Director
AGE
60
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
26. Dec 18 Buy William Doyle Individual 20. Dec 18 20. Dec 18 2,000 €5.69 €11,387
13. Dec 18 Sell Richard Russell Individual 12. Dec 18 12. Dec 18 -3,117 €7.01 €-21,841
12. Dec 18 Buy William Doyle Individual 10. Dec 18 11. Dec 18 6,000 €7.06 €42,212
21. Nov 18 Buy William Doyle Individual 20. Nov 18 20. Nov 18 2,000 €7.20 €14,391
15. Oct 18 Buy William Doyle Individual 11. Oct 18 11. Oct 18 600 €8.66 €5,193
03. Oct 18 Sell Index Ventures Company 01. Oct 18 01. Oct 18 -15,444 €10.67 €-164,806
01. Oct 18 Sell Index Ventures Company 27. Sep 18 28. Sep 18 -66,273 €10.86 €-718,356
19. Sep 18 Buy William Doyle Individual 17. Sep 18 17. Sep 18 1,800 €8.98 €16,173
17. Sep 18 Buy William Doyle Individual 13. Sep 18 14. Sep 18 2,200 €9.00 €19,808
11. Sep 18 Buy William Doyle Individual 10. Sep 18 11. Sep 18 8,011 €8.53 €67,744
X
Management checks
We assess Minerva Neurosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Minerva Neurosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company’s lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIb clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company’ preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, NV for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

Details
Name: Minerva Neurosciences, Inc.
4MN
Exchange: DB
Founded: 2007
$254,719,483
39,025,471
Website: http://www.minervaneurosciences.com
Address: Minerva Neurosciences, Inc.
1601 Trapelo Road,
Suite 286,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM NERV Common Stock Nasdaq Global Market US USD 01. Jul 2014
DB 4MN Common Stock Deutsche Boerse AG DE EUR 01. Jul 2014
Number of employees
Current staff
Staff numbers
13
Minerva Neurosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:49
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/09
Last earnings filing: 2019/03/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.